- Home
- IRON vs NBHC Comparison
IRON vs NBHC Comparison
Compare IRON & NBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- NBHC
- Stock Information
- Founded
- IRON 2017
- NBHC 2009
- Country
- IRON United States
- NBHC United States
- Employees
- IRON N/A
- NBHC N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- NBHC Major Banks
- Sector
- IRON Health Care
- NBHC Finance
- Exchange
- IRON Nasdaq
- NBHC Nasdaq
- Market Cap
- IRON 1.4B
- NBHC 1.4B
- IPO Year
- IRON N/A
- NBHC 2012
- Fundamental
- Price
- IRON $44.24
- NBHC $36.97
- Analyst Decision
- IRON Strong Buy
- NBHC Hold
- Analyst Count
- IRON 10
- NBHC 5
- Target Price
- IRON $83.80
- NBHC $46.80
- AVG Volume (30 Days)
- IRON 397.9K
- NBHC 296.1K
- Earning Date
- IRON 05-07-2025
- NBHC 04-22-2025
- Dividend Yield
- IRON N/A
- NBHC 3.13%
- EPS Growth
- IRON N/A
- NBHC N/A
- EPS
- IRON N/A
- NBHC 2.89
- Revenue
- IRON N/A
- NBHC $389,883,000.00
- Revenue This Year
- IRON N/A
- NBHC $13.64
- Revenue Next Year
- IRON N/A
- NBHC $6.70
- P/E Ratio
- IRON N/A
- NBHC $12.84
- Revenue Growth
- IRON N/A
- NBHC N/A
- 52 Week Low
- IRON $28.25
- NBHC $32.83
- 52 Week High
- IRON $68.73
- NBHC $51.76
- Technical
- Relative Strength Index (RSI)
- IRON 45.99
- NBHC 53.69
- Support Level
- IRON $40.36
- NBHC $35.86
- Resistance Level
- IRON $47.21
- NBHC $37.42
- Average True Range (ATR)
- IRON 2.87
- NBHC 0.92
- MACD
- IRON 0.10
- NBHC 0.30
- Stochastic Oscillator
- IRON 37.67
- NBHC 87.74
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About NBHC National Bank Holdings Corporation
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit card, wire transfer, automated clearing house, and electronic bill payments.